Saturday 17 October 2026
Export CTXR’s income statement to Excel — free account
Citius Pharmaceuticals, Inc.
CTXR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 57.5% and free cash flow fell 60.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.46
0.00
0.00%
Follow CTXR
Citius Pharmaceuticals, Inc. (CTXR) P/E ratio
Citius Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| ICU SeaStar Medical Holding Corporation compare | n/m |
| CTXR Citius Pharmaceuticals, Inc. | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| PLUR Pluri Inc. compare | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | n/m |
| HIND Vyome Holdings, Inc. compare | 0.0× |
| ASBP Aspire-Lakewood Holdings, Inc. compare | 0.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)